The Influence of Need-Based, Continuous, Low-Dose Iron Replacement on Hemoglobin Levels in Hemodialysis Patients Treated With Erythropoiesis-Stimulating Agents

Artificial Organs

Volumn 35, Issue 1, 2011, Pages 63-68

  Malovrh, Marko ^a   Hojs, Nina ^b   Premru, Vladimir ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Anemia management; Erythropoiesis stimulating agents; Hemodialysis patients; Intravenous iron

Indexed keywords

ARTIFICIAL ORGANS; BODY FLUIDS; DIALYSIS; HEMODIALYZERS; HEMOGLOBIN; PATIENT MONITORING; PATIENT TREATMENT; RATS; SUGAR (SUCROSE);

ANEMIA MANAGEMENT; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; HAEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN LEVELS; INTRAVENOUS IRON; IRON SUCROSE; LOW DOSE; OPTIMAL SCHEDULE;

IRON;

ANTIANEMIC AGENT; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 78651468098     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2010.01037.x     Document Type: Article

References (25)

1. de Francisco AL. Key insights into present and future treatments of anaemia in CKD patients. NDT Plus 2009;2 (Suppl. 1):i1-2.
2. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009;22:70-7.
3. Coyne DW. Introduction to "A road map for intravenous iron and anemia management: preparing for the future." Am J Kidney Dis 2008;52 (Suppl. 6):S1-4.
4. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009;16:94-100.
5. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007;18:382-93.
6. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 2009;16:143-51.
7. Agarwal R. Iron therapy in CKD patients-harm or benefit? Chronic kidney disease expert column. Medscape Nephrology 2008. Available at: Accessed October 7 2008.
8. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998;13:82-8.
9. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9.
10. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
11. Deicher R, Ziai F, Cohen G, Müllner M, Hörl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64:728-36.
12. Deicher R, Hörl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006;36:301-9.
13. Schiesser D, Binet I, Tsinalis D, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006;21:2841-5.
14. Canavese C, Bergamo D, Ciccone G, et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 2004;19:1564-70.
15. Spiegel DM, Chertow G. Lost without directions: lessons from the anemia debate and the drive study. Clin J Am Soc Nephrol 2009;4:1009-10.
16. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9.
17. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-91.
18. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
19. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36.
20. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-7.
21. Coyne DW. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 2008;52 (Suppl. 6): S14-20.
22. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
23. Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-7.
24. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001;107:1545-53.
25. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.